Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q

• Published in: Journal of thoracic disease Vol. 12; no. 5; pp. 2771 - 2780
• Main Authors: Song, Yang, Jia, Ziqi, Wang, Yadong, Wang, Yanyu, Liu, Peng, Zhang, Shuyang, Bing, Zhongxing, Cao, Lei, Cao, Zhili, Rossi, Elisabetta, Zamarchi, Rita, Denis, Marc G, Camps, Carlos, Fernandez-Diaz, Amaya B, Liang, Naixin, Li, Shanqing
• Format: Journal Article
• Language: English
• Published: China AME Publishing Company 01-05-2020
• Subjects: iMDT Corner; treatment strategy; tyrosine kinase inhibitors (TKIs) re-challenge; osimertinib resistance; Non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR) L718Q
• ISSN: 2072-1439; 2077-6624
• DOI: 10.21037/jtd.2020.03.29

Epidermal growth factor receptor (EGFR) L718Q is a rare resistant mutation which independently leads to third-generation tyrosine kinase inhibitor (TKI) resistance. Although a few studies have examined its resistance mechanisms, no effective treatment strategy has yet been proposed for patients with this mutation. Here, we report an effective treatment strategy for the rare EGFR L718Q mutation for the first time. A 44-year-old Chinese male patient initially presented with the sensitizing EGFR L858R mutation, and the progression-free survival (PFS) time after initial icotinib treatment was 9 months. When the progression of the disease (PD) and the EGFR T790M mutation were identified, he did not respond to the osimertinib treatment. Through comprehensive next-generation sequencing (NGS) of the surgical specimen, the rare EGFR L718Q mutation was eventually identified as having a frequency of 68.84%, together with an EGFR amplification with a copy number of 11.54. The previous treatment response was retrospectively explained, and the patient faced the challenge of not being able to benefit from any targeted therapy. Following chemotherapy with a personalized regimen which effectively modified the proportion of sensitive and resistant cells, significant response to osimertinib re-challenge was observed, and another PFS of 4.7 months was achieved. Unfortunately, four EGFR mutations, EGFR L858, T790M, L718Q, and C797S, were simultaneously detected in his late stage, and led to further progression of disease.